

TÜV Rheinland LGA Products GmbH • 51105 Köln

*Foshan MIC Medical Technology CO., Ltd.  
Unit 501-1 and 503, 5th Floor, No. 7 Building, Zone A, Hantian Industrial Park 17th  
Shenhai Road, Guicheng, Nanhai, Foshan,  
528200 Guangdong,  
P.R. China*

Contact

Tel. +49 911 655-5225  
Mail: [medical-products@de.tuv.com](mailto:medical-products@de.tuv.com)

Date May 14, 2024

### **Notified Body Confirmation Letter**

Reference. : MICME\_PLA\_2024-05-08; order #10924297

To whom it may concern,

### **Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices.**

This letter confirms that **TÜV Rheinland LGA Products GmbH**, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number **0197** on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

*Foshan MIC Medical Technology CO., Ltd.  
Unit 501-1 and 503, 5th Floor, No. 7 Building, Zone A, Hantian Industrial Park 17th  
Shenhai Road, Guicheng, Nanhai, Foshan,  
528200 Guangdong,  
P.R. China*  
SRN Number (if available): CN-MF-000027750

The devices covered by the formal application and the written agreement mentioned above are identified in the tables below. Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after May 26, 2021 but before March 20, 2023 without having been withdrawn, this letter also confirms that the manufacturer either signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by March 20, 2023 for the relevant devices.

TÜV Rheinland  
LGA Products GmbH

Am Grauen Stein  
51105 Köln  
Germany

Headquarter

Tillystraße 2  
90431 Nuremberg

Phone. +49 911 655 5225  
Fax +49 911 655 5226  
[service@de.tuv.com](mailto:service@de.tuv.com)  
[www.tuv.com/safety](http://www.tuv.com/safety)

Board of Management

Dipl.-Ing.  
Thomas Weigand, Spokesman

Dipl.-Kfm.  
Dr. Jörg Schlösser

Nuremberg HRB 26013  
VAT No.: DE 811835490

Chairman of the  
Supervisory Board

Dr.-Ing. Michael Fübi

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- May 26, 2026 for Class III custom-made implantable devices
- December 31, 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- December 31, 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- December 31, 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body



Samuel QIN

Certification body

**Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:**

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
<p><b>Oxygen concentrator</b>  <b>Model No.: CP101, CP501, AI-5, AII-5, CP502, CP503, CP505, CP506</b></p> <p><b>Basic UDI-DI:</b>  <b>69703798506CPA20240507G8</b></p>	<p>Class IIb excluding Class IIb implantable non-WET</p>	<p>N/A</p>	<p>Certificate # HD 60146956 0001                      NB #0197</p> <p>Note: model No.: CP502, CP503, CP505, CP506 are not covered by MDD certificate.</p>

**Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:**

<b>Device name or Basic UDI-DI (under MDR application)</b>	<b>MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)</b>	<b>If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device</b>	<b>MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification</b>
None			

**Confirmation Letter Revision History**

<b>Date</b>	<b>NB internal reference traceable to each version of the letter</b>	<b>Action</b>
2024-05-14	MICME_CL607_2024-05-14	Initial issue